June 21, 2010 (FinancialWire) — AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a biotech company developing early detection and drug technologies to enable cancer treatments, said that it has entered into an option agreement to license specific antibodies to KellBenx Inc., a private biotech firm.

New York-based KellBenx focuses on the development of non-invasive prenatal diagnosis for specific genetic and other heritable disorders.

Under the license, KellBenx will secure exclusive worldwide rights to commercialize the antibodies, which enable the extraction of clinically relevant information from maternal blood through a test that could be widely available as early as 2011.

Fetal Nucleated Red Blood Cells, which have been identified in maternal blood, can be a source for monitoring and diagnosis of maternal, fetal, and neonatal health and disease, according to the companies.

The KellBenx process involves the enrichment of FNRBC’s with the antibodies licensed from AdnaGen, namely Monoclonal Antibodies with Specificity for Fetal Erythroid Cells, to perform chromosomal or genetic analysis to identify markers of potential disorders.

Texas-based OncoVista is a biopharmaceutical technology company commercializing diagnostic tests for metastatic tumors, as well as developing targeted anticancer therapies by utilizing tumor-associated biomarkers.

The firm has developed diagnostic kits for breast, colon, ovarian, and prostate cancers, and currently markets diagnostic kits in Europe for the detection of circulating tumor cells in patients with breast, colon and prostate cancer.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [biomedphrm] [nwdlsldw] [btnwswntb] [tchnlgy] [ddnstcsct]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.